Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy.

Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy.

Show other versions (1)

Activation of invariant CD1d-dependent NK T cells (iNKT cells) in vivo through administration of the glycolipid ligand alpha-galactosylceramide (alpha-GalCer) or the sphingosine-truncated alpha-GalCer analog OCH leads to CD40 signaling as well as the release of soluble molecules including type 1 and...

Full description

Bibliographic Details
Main Authors:	Silk, J, Hermans, I, Gileadi, U, Chong, T, Shepherd, D, Salio, M, Mathew, B, Schmidt, R, Lunt, S, Williams, K, Stratford, I, Harris, A, Cerundolo, V
Format:	Journal article
Language:	English
Published:	2004

Similar Items

Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy
by: Silk, J, et al.
Published: (2004)

NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
by: Hermans, I, et al.
Published: (2003)

Dendritic cell function can be modulated through cooperative actions of TLR ligands and invariant NKT cells.
by: Hermans, I, et al.
Published: (2007)

Nonglycosidic agonists of invariant NKT cells for use as vaccine adjuvants.
by: Reddy, BG, et al.
Published: (2009)

Biology of CD1- and MR1-restricted T cells.
by: Salio, M, et al.
Published: (2014)

Nonglycosidic CD1d lipid ligands activate human and murine invariant NKT cells
by: Silk, J, et al.
Published: (2008)

CpG-matured murine plasmacytoid dendritic cells are capable of in vivo priming of functional CD8 T cell responses to endogenous but not exogenous antigens.
by: Salio, M, et al.
Published: (2004)

Cutting edge: nonglycosidic CD1d lipid ligands activate human and murine invariant NKT cells.
by: Silk, J, et al.
Published: (2008)

Dendritic cells: a journey from laboratory to clinic.
by: Cerundolo, V, et al.
Published: (2004)

Recent advances in processing and presentation of CD1 bound lipid antigens.
by: Salio, M, et al.
Published: (2010)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
by: Xiaopeng Tian, et al.
Published: (2023-04-01)

The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy
by: Yanlin Yu
Published: (2023-04-01)

Harnessing the power of invariant natural killer T cells in cancer immunotherapy
by: Bedard, M, et al.
Published: (2017)

Mechanisms of Resistance to NK Cell Immunotherapy
by: Christian Sordo-Bahamonde, et al.
Published: (2020-04-01)

NK cell-based tumor immunotherapy
by: Hao Zhang, et al.
Published: (2024-01-01)

NK Cell-Based Glioblastoma Immunotherapy
by: Irene Golán, et al.
Published: (2018-12-01)

Harnessing invariant NKT cells in vaccination strategies.
by: Cerundolo, V, et al.
Published: (2009)

A dominant role for the immunoproteasome in CD8+ T cell responses to murine cytomegalovirus.
by: Hutchinson, S, et al.
Published: (2011)

Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
by: Xinyu Wu, et al.
Published: (2022-12-01)

NK Cell-Based Immunotherapy in Renal Cell Carcinoma
by: Iñigo Terrén, et al.
Published: (2020-01-01)

Flow cytometric visualisation of cytokine production by CD3-CD56+ NK cells and CD3+CD56+ NK-T cells in whole blood.
by: Mendes, R, et al.
Published: (2000)

Activation of human mucosal-associated invariant T cells induces CD40L-dependent maturation of monocyte-derived and primary dendritic cells
by: Salio, M, et al.
Published: (2018)

PECULIARITIES OF NK CELLS DIFFERENTIATION: CD56dim AND CD56bright NK CELLS AT PREGNANCY AND IN NON-PREGNANT STATE
by: V. A. Mikhailova, et al.
Published: (2017-01-01)

Thymic NK-Cells and Their Potential in Cancer Immunotherapy
by: Forbes C, et al.
Published: (2024-03-01)

NK Cell-Based Immunotherapy in Colorectal Cancer
by: Mariella Della Chiesa, et al.
Published: (2022-06-01)

Harnessing NK Cell Checkpoint-Modulating Immunotherapies
by: Sachin Kumar Singh Chauhan, et al.
Published: (2020-07-01)

Editorial: NK cells in viral immunology and immunotherapy
by: Sachin Mulik, et al.
Published: (2023-05-01)

NK Cell-Based Immunotherapy in Cancer Metastasis
by: Seila Lorenzo-Herrero, et al.
Published: (2018-12-01)

Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies
by: Barbara Seliger, et al.
Published: (2022-08-01)

Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model.
by: Hermans, I, et al.
Published: (2003)

Histone deacetylase inhibitors enhance CD4 T cell susceptibility to NK cell killing but reduce NK cell function
by: Pace, M, et al.
Published: (2016)

Structural and functional aspects of lipid binding by CD1 molecules.
by: Silk, J, et al.
Published: (2008)

The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy
by: Elena V. Abakushina, et al.
Published: (2021-11-01)

Generation of CD1 tetramers as a tool to monitor glycolipid-specific T cells.
by: Gadola, S, et al.
Published: (2003)

CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma
by: Ioana Sonya Ciulean, et al.
Published: (2023-11-01)

Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy
by: Shahryar Khoshtinat Nikkhoi, et al.
Published: (2023-01-01)

Improved characterization and translation of NK cells for canine immunotherapy
by: Aryana M. Razmara, et al.
Published: (2024-02-01)

Chasing Uterine Cancer with NK Cell-Based Immunotherapies
by: Vijay Kumar, et al.
Published: (2022-12-01)

Targeting NK Cells to Enhance Melanoma Response to Immunotherapies
by: Hansol Lee, et al.
Published: (2021-03-01)

Challenges and Prospects for Designer T and NK Cells in Glioblastoma Immunotherapy
by: Victoria Smith Arnesen, et al.
Published: (2021-10-01)